61 related articles for article (PubMed ID: 25014961)
21. Aptamer-nanoparticle bioconjugates enhance intracellular delivery of vinorelbine to breast cancer cells.
Zhou W; Zhou Y; Wu J; Liu Z; Zhao H; Liu J; Ding J
J Drug Target; 2014 Jan; 22(1):57-66. PubMed ID: 24156476
[TBL] [Abstract][Full Text] [Related]
22. Reducible polyamidoamine-magnetic iron oxide self-assembled nanoparticles for doxorubicin delivery.
Chen J; Shi M; Liu P; Ko A; Zhong W; Liao W; Xing MM
Biomaterials; 2014 Jan; 35(4):1240-8. PubMed ID: 24239110
[TBL] [Abstract][Full Text] [Related]
23. ERBB-2 (HER2/neu) gene copy number, p185HER-2 overexpression, and intratumor heterogeneity in human breast cancer.
Szöllösi J; Balázs M; Feuerstein BG; Benz CC; Waldman FM
Cancer Res; 1995 Nov; 55(22):5400-7. PubMed ID: 7585609
[TBL] [Abstract][Full Text] [Related]
24. [Effects of interferon-gamma on Her-2/neu expression and antitumor activity of 131I-Herceptin in breast cancer cell lines].
Fan YX; Luo RC; Fang YX; Yan X; Lu CW
Ai Zheng; 2006 Apr; 25(4):443-6. PubMed ID: 16613677
[TBL] [Abstract][Full Text] [Related]
25. [Establishment of a bioluminescent MDA-MB-231 cell line for in vivo imaging of human triple-negative breast cancer xenograft].
Wang K; Xie SM; He JJ; Ren Y; Xia HB; Zhang XW
Nan Fang Yi Ke Da Xue Xue Bao; 2011 Nov; 31(11):1812-8. PubMed ID: 22126756
[TBL] [Abstract][Full Text] [Related]
26. Epidermal growth factor-ferritin H-chain protein nanoparticles for tumor active targeting.
Li X; Qiu L; Zhu P; Tao X; Imanaka T; Zhao J; Huang Y; Tu Y; Cao X
Small; 2012 Aug; 8(16):2505-14. PubMed ID: 22619186
[TBL] [Abstract][Full Text] [Related]
27. A multimodal magnetic resonance imaging nanoplatform for cancer theranostics.
Benyettou F; Lalatonne Y; Chebbi I; Di Benedetto M; Serfaty JM; Lecouvey M; Motte L
Phys Chem Chem Phys; 2011 Jun; 13(21):10020-7. PubMed ID: 21409252
[TBL] [Abstract][Full Text] [Related]
28. erbB family receptor expression and growth regulation in a newly isolated human breast cancer cell line.
Ethier SP; Kokeny KE; Ridings JW; Dilts CA
Cancer Res; 1996 Feb; 56(4):899-907. PubMed ID: 8631031
[TBL] [Abstract][Full Text] [Related]
29. [Study of the correlation between HER-2 gene and lymphangiogenesis and their prognostic significance in human breast cancer].
Zhang GH; Yang WT; Zhou XY; Zeng Y; Lu HF; Shi DR
Zhonghua Yi Xue Za Zhi; 2007 Jan; 87(3):155-60. PubMed ID: 17425844
[TBL] [Abstract][Full Text] [Related]
30. Intrathecal magnetic drug targeting using gold-coated magnetite nanoparticles in a human spine model.
Lueshen E; Venugopal I; Kanikunnel J; Soni T; Alaraj A; Linninger A
Nanomedicine (Lond); 2014; 9(8):1155-69. PubMed ID: 23862614
[TBL] [Abstract][Full Text] [Related]
31. Epidermal growth factor receptor vIII enhances tumorigenicity in human breast cancer.
Tang CK; Gong XQ; Moscatello DK; Wong AJ; Lippman ME
Cancer Res; 2000 Jun; 60(11):3081-7. PubMed ID: 10850460
[TBL] [Abstract][Full Text] [Related]
32. Impedance spectroscopy assisted by magnetic nanoparticles as a potential biosensor principle for breast cancer cells in suspension.
Silva JG; Cárdenas RA; Quiróz AR; Sánchez V; Lozano LM; Pérez NM; López J; Villanueva C; González CA
Physiol Meas; 2014 Jun; 35(6):931-41. PubMed ID: 24846525
[TBL] [Abstract][Full Text] [Related]
33. Cetuximab enhances the anti-proliferative effect of trastuzumab in ERBB2 over-expressing breast cancer cells--preliminary study.
Uberall I; Krízová K; Steigerová J
Klin Onkol; 2011; 24(5):356-60. PubMed ID: 22070017
[TBL] [Abstract][Full Text] [Related]
34. Correlation of GREB1 mRNA with protein expression in breast cancer: validation of a novel GREB1 monoclonal antibody.
Hnatyszyn HJ; Liu M; Hilger A; Herbert L; Gomez-Fernandez CR; Jorda M; Thomas D; Rae JM; El-Ashry D; Lippman ME
Breast Cancer Res Treat; 2010 Jul; 122(2):371-80. PubMed ID: 19842031
[TBL] [Abstract][Full Text] [Related]
35. Detectability of Her2 positive tumors using monoclonal antibody conjugated iron oxide nanoparticles in MRI.
Oghabian MA; Jeddi-Tehrani M; Zolfaghari A; Shamsipour F; Khoei S; Amanpour S
J Nanosci Nanotechnol; 2011 Jun; 11(6):5340-4. PubMed ID: 21770186
[TBL] [Abstract][Full Text] [Related]
36. Targeting HER2+ breast cancer cells: lysosomal accumulation of anti-HER2 antibodies is influenced by antibody binding site and conjugation to polymeric nanoparticles.
Owen SC; Patel N; Logie J; Pan G; Persson H; Moffat J; Sidhu SS; Shoichet MS
J Control Release; 2013 Dec; 172(2):395-404. PubMed ID: 23880472
[TBL] [Abstract][Full Text] [Related]
37. Targeting HER-2 over expressed breast cancer cells with 2-cyclohexyl-N-[(Z)-(substituted phenyl/furan-2-yl/thiophene-2-yl)methylidene]hydrazinecarbothioamide.
Bhat MA; Al-Dhfyan A; Khan AA; Al-Harbi N; Manogaran PS; Alanazi AM; Fun HK; Al-Omar MA
Bioorg Med Chem Lett; 2015 Jan; 25(1):83-7. PubMed ID: 25466196
[TBL] [Abstract][Full Text] [Related]
38. Selective killing of cancer cells by nanoparticle-assisted ultrasound.
Kosheleva OK; Lai TC; Chen NG; Hsiao M; Chen CH
J Nanobiotechnology; 2016 Jun; 14(1):46. PubMed ID: 27301243
[TBL] [Abstract][Full Text] [Related]
39. Progress in targeting tumor cells by using drug-magnetic nanoparticles conjugate.
Nowicka AM; Kowalczyk A; Jarzebinska A; Donten M; Krysinski P; Stojek Z; Augustin E; Mazerska Z
Biomacromolecules; 2013 Mar; 14(3):828-33. PubMed ID: 23327587
[TBL] [Abstract][Full Text] [Related]
40. Alpha-particle emitting atomic generator (Actinium-225)-labeled trastuzumab (herceptin) targeting of breast cancer spheroids: efficacy versus HER2/neu expression.
Ballangrud AM; Yang WH; Palm S; Enmon R; Borchardt PE; Pellegrini VA; McDevitt MR; Scheinberg DA; Sgouros G
Clin Cancer Res; 2004 Jul; 10(13):4489-97. PubMed ID: 15240541
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
